Feraccru®
Feraccru® (Ferric Maltol) is a stable, non-salt, oral formulation of ferric iron, which has a novel mechanism of action compared to salt-based oral iron therapies.
For further information on Feraccru® please click here.
Pipeline product candidates
PT20
PT20 is a novel iron-based phosphate binder that we are developing for the treatment of hyperphosphatemia. The integration of adipic acid to form PT20 increases the phosphate binding capacity by a factor of three, compared to the unmodified iron oxide. The manufacturing process also results in particles of a very small size, which maximises the surface available for phosphate binding.
PT20 is exclusively licensed from the Medical Research Council in the United Kingdom.
PT30 and PT40
PT30 is a novel IV iron formulation and PT40 is being developed to be the first generic version of iron sucrose.
Carl Sterrit
Chief Executive Officer and Co-Founder
James Karis
Non-Executive Director
Peter Llewellyn-Davies
Non-Executive Director
Rolf Hoffman
Non-Executive Director
Hans Peter Hasler
Non-Exectuive Director
Tim Watts
Interim CFO
Dr Mark Sampson
Chief Medical Officer
Dr Jackie Mitchell
VP Regulatory Affairs and Quality
David Childs
Director of Product Supply and Commercial Alliances
Lucy Bailey
Senior Legal Counsel and Company Secretary
Northern Design Centre
Baltic Business Quarter
Gateshead Quays, NE8 3DF
t+44 (0) 191 511 8500
Sihleggstrasse 23,
8832 Wollerau
Switzerland
t+41 (0) 435 080 781
Oranienburger Str. 3
c/o Lambsdorff Rechtsanwälte PartGmbB
10178 Berlin
Germany
t+44 (0) 207 186 8500
Nominated Advisor and Joint Broker
Peel Hunt LLP, 120 London Wall London EC2Y 5ET
Tel: +44 (0)20 7418 8900
Joint Broker
finnCap, 60 New Broad Street London EC2M 1JJ
Tel: +44 (0)20 7220 0500
Auditors
KPMG LLP, Quayside House, 110 Quayside Newcastle Upon Tyne NE1 3DX
Tel: +44 (0)19 1401 3700
Legal Advisors
Stephenson Harwood LLP, 1 Finsbury Circus, London EC2M 7SH
Tel: +44 (0)20 7329 4422
Tax Advisors
Ernst & Young LLP, Citygate St James’ Boulevard Newcastle upon Tyne NE1 4JD
Tel: +44 (0)19 1247 2500
Investor Relations and Financial PR
Walbrook PR Ltd, 4 Lombard Street London EC3V 9HD
Tel: +44 (0)20 7933 8780
Email: [email protected]
Registrar
Link Asset Services Limited, The Registry 34 Beckenham Road Beckenham Kent BR3 4TU
Tel: +44 (0)871 664 0300
Shield Therapeutics plc
Shield Therapeutics plc, Northern Design Centre Gateshead Quays, Gateshead NE8 3DF
Tel: +44 (0)191 511 8500
Email: [email protected]
Analyst Coverage
The following analysts currently issue reports on Shield Therapeutics:
Company Analyst
Liberum Graham Doyle
Peel Hunt Amy Walker
Edison Dr Susie Jana
Hardman & Co Dr Dorothea Hill
Capital Network Emma Ulker
finnCap Mark Brewer
Click here to view share price summary.